News you may have missed from AHA 2023: SELECT, artificial intelligence, gene editing, more
Click Here to Manage Email Alerts
Healio | Cardiology Today compiled a list of the top news from the 2023 American Heart Association Scientific Sessions.
See below for the news readers were most interested in, including results of the SELECT, ORFAN and ORBITA-2 trials and more.
Read all of Healio’s AHA 2023 coverage here.
Semaglutide cuts cardiovascular risk by 20% in people with heart disease, obesity: SELECT
In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg (Wegovy, Novo Nordisk) was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.
Perspective from Erin D. Michos, MD, MHS, Eugene Yang, MD, and Sean Heffron, MD. Read more
AI-enabled technology independently predicts cardiac events based on coronary inflammation
An artificial intelligence-based technology (CaRi-Heart, Caristo Diagnostics) that evaluates coronary inflammation predicted risk for cardiac events in patients undergoing coronary CTA, according to results of the ORFAN study.
Perspective from Alan C. Kwan, MD. Read more
Early study suggests gene editing can lower LDL cholesterol via PCSK9 inhibition
A novel single-dose CRISPR base-editing infusion (VERVE-101, Verve Therapeutics) for patients with heterozygous familial hypercholesterolemia and advanced CAD reduced serum PCSK9 and lowered LDL by up to 55% in one patient.
Perspective from Karol Watson, MD, PhD. Read more
PCI improves angina symptoms vs. sham procedure in patients with stable CAD: ORBITA-2
In patients with stable angina and evidence of ischemia, PCI improved angina symptoms at 12 weeks compared with a sham procedure, according to results from the ORBITA-2 trial.
Perspective from Samin K. Sharma, MD. Read more
Novel PCSK9 inhibitor recaticimab linked to durable LDL reduction
Recaticimab (Jiangsu Hengrui Pharmaceuticals), a novel anti-PCSK9 drug, conferred significant LDL reductions at 48 weeks in a cohort of patients with mixed hyperlipidemias already on statin therapy in the REMAIN-2 trial. Read more
Injectable antihypertensive drug lowers blood pressure for up to 6 months
Zilebesiran (Alnylam), an investigational subcutaneous RNA interference therapeutic, lowered systolic blood pressure at 3 months and sustained the reduction to 6 months, according to results of the phase 2 KARDIA-1 trial.
Perspective from Sandra J. Taler, MD. Read more
Lepodisiran substantially lowers Lp(a) in early trial
In a phase 1 study, lepodisiran was well-tolerated and produced dose-dependent reductions in lipoprotein(a) concentrations in adults without CVD who had elevated lipoprotein(a) levels.
Perspective from Karol E. Watson, MD, PhD. Read more
Factor XI inhibitor for AF drastically reduces bleeding vs. rivaroxaban in phase 2 trial
In the phase 2b AZALEA-TIMI 71 trial, abelacimab (Anthos Therapeutics), a novel factor XI inhibitor, drastically reduced bleeding compared with rivaroxaban in patients with atrial fibrillation requiring stroke prevention.
Perspective from Christine M. Albert, MD, MPH. Read more
Smartphone-based speech analysis app may predict worsening heart failure
A novel smartphone-based speech analysis technology (HearO, Cordio Medical) predicted worsening heart failure that could lead to hospitalization.
Perspective from Clyde W. Yancy, MD, MSc. Read more
Inflammation predicts events more than cholesterol in high-risk statin-intolerant patients
In the CLEAR Outcomes cohort of patients with statin intolerance, inflammation predicted risk for CV events and death more strongly than cholesterol.
Perspective from Howard Weintraub, MD. Read more
Collapse
Healio Coverage
Click Here to Manage Email Alerts